Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488)
Health Care · Pharmaceuticals · CN
CN¥5.51
-6.29% today · +22.4% 1Y
Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $894.96M and employs 2,731 people.
Over the last twelve months the share price has gained 22.4%, trading between 3.68 and 8.44.
Tweenvest scores Tianjin Tianyao Pharmaceuticals Co., Ltd. across four factors: quality 70/100, value 11/100, growth 27/100, dividend 28/100. Its strongest factor is quality.
600488 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $894.96M
- Revenue (TTM)
- $395.86M
- P/E
- 225.15
- EPS
- 0.02
- Dividend yield
- 0.94%
- Beta (5Y)
- -0.03
- 52-week high
- CN¥8.44
- 52-week low
- CN¥3.68
- Avg volume (3M)
- —
- Shares outstanding
- 1.09B
- Employees
- 2,731
- Next earnings
- —
About Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tianjin Tianyao Pharmaceuticals Co., Ltd. is a Chinese enterprise primarily engaged in the research, manufacturing, and export of active pharmaceutical ingredients (APIs) across the Asian market. The company's core product offerings include APIs and formulated drugs for corticosteroid, cardio cerebrovascular, and analgesic applications. Its extensive portfolio of bulk drug substances encompasses numerous compounds such as dexamethasone and its various salts and esters, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone and its derivatives, clobetasol propionate, betamethasone, and methylprednisolone. Based in Tianjin, China, Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
- ISIN
- CNE000001840
- Founded
- 1939
- Listed since
- Jun 18, 2001
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.50 | -0.01% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.20 | +0.02% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.